[go: up one dir, main page]

ITUB20153652A1 - Microsfere contenenti lattoni macrociclici antielminitici - Google Patents

Microsfere contenenti lattoni macrociclici antielminitici

Info

Publication number
ITUB20153652A1
ITUB20153652A1 ITUB2015A003652A ITUB20153652A ITUB20153652A1 IT UB20153652 A1 ITUB20153652 A1 IT UB20153652A1 IT UB2015A003652 A ITUB2015A003652 A IT UB2015A003652A IT UB20153652 A ITUB20153652 A IT UB20153652A IT UB20153652 A1 ITUB20153652 A1 IT UB20153652A1
Authority
IT
Italy
Prior art keywords
lattons
elminitic
microspheres containing
containing macrocyclic
macrocyclic anti
Prior art date
Application number
ITUB2015A003652A
Other languages
English (en)
Inventor
Giuseppe Corace
Eva Morbidelli
Laura Bertocchi
Lauretta Montecchi
Original Assignee
Fatro Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fatro Spa filed Critical Fatro Spa
Priority to ITUB2015A003652A priority Critical patent/ITUB20153652A1/it
Priority to RS20201395A priority patent/RS61100B1/sr
Priority to AU2016321801A priority patent/AU2016321801B2/en
Priority to KR1020247021000A priority patent/KR102752755B1/ko
Priority to PCT/EP2016/070921 priority patent/WO2017045966A1/en
Priority to LTEP16770213.3T priority patent/LT3349726T/lt
Priority to HRP20201783TT priority patent/HRP20201783T1/hr
Priority to ES16770213T priority patent/ES2848559T3/es
Priority to EP16770213.3A priority patent/EP3349726B1/en
Priority to HUE16770213A priority patent/HUE052553T2/hu
Priority to PL16770213T priority patent/PL3349726T3/pl
Priority to DK16770213.3T priority patent/DK3349726T3/da
Priority to KR1020177035710A priority patent/KR20180052559A/ko
Priority to SM20200625T priority patent/SMT202000625T1/it
Priority to SI201630970T priority patent/SI3349726T1/sl
Priority to JP2017564811A priority patent/JP6781717B2/ja
Priority to US15/735,233 priority patent/US10603278B2/en
Priority to CA2989092A priority patent/CA2989092C/en
Priority to PT167702133T priority patent/PT3349726T/pt
Publication of ITUB20153652A1 publication Critical patent/ITUB20153652A1/it
Priority to CY20201101059T priority patent/CY1123554T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Feed For Specific Animals (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
ITUB2015A003652A 2015-09-16 2015-09-16 Microsfere contenenti lattoni macrociclici antielminitici ITUB20153652A1 (it)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ITUB2015A003652A ITUB20153652A1 (it) 2015-09-16 2015-09-16 Microsfere contenenti lattoni macrociclici antielminitici
HUE16770213A HUE052553T2 (hu) 2015-09-16 2016-09-06 Anthelmintikus hatású makrociklusos laktonokat tartalmazó mikrogömbök
PL16770213T PL3349726T3 (pl) 2015-09-16 2016-09-06 Mikrosfery zawierające przeciwrobacze laktony makrocykliczne
KR1020247021000A KR102752755B1 (ko) 2015-09-16 2016-09-06 구충제 마크로시클릭 락톤을 포함하는 미세구
PCT/EP2016/070921 WO2017045966A1 (en) 2015-09-16 2016-09-06 Microspheres containing anthelmintic macrocyclic lactones
LTEP16770213.3T LT3349726T (lt) 2015-09-16 2016-09-06 Mikrosferos, turinčios antihelmintinių makrociklinių laktonų
HRP20201783TT HRP20201783T1 (hr) 2015-09-16 2016-09-06 Mikrosfere koje sadrže anthelmintske makrocikličke laktone
ES16770213T ES2848559T3 (es) 2015-09-16 2016-09-06 Microesferas que contienen lactonas macrocíclicas antihelmínticas
EP16770213.3A EP3349726B1 (en) 2015-09-16 2016-09-06 Microspheres containing anthelmintic macrocyclic lactones
RS20201395A RS61100B1 (sr) 2015-09-16 2016-09-06 Mikrosfere koje sadrže antelmintične makrociklične laktone
AU2016321801A AU2016321801B2 (en) 2015-09-16 2016-09-06 Microspheres containing anthelmintic macrocyclic lactones
DK16770213.3T DK3349726T3 (da) 2015-09-16 2016-09-06 Mikrosfærer indeholdende antihelmintiske makrocykliske lactoner
KR1020177035710A KR20180052559A (ko) 2015-09-16 2016-09-06 구충제 마크로시클릭 락톤을 포함하는 미세구
SM20200625T SMT202000625T1 (it) 2015-09-16 2016-09-06 Microsfere contenenti lattoni macrociclici antielmintici
SI201630970T SI3349726T1 (sl) 2015-09-16 2016-09-06 Mikrosfere, ki vsebujejo antihelmintske makrociklične laktone
JP2017564811A JP6781717B2 (ja) 2015-09-16 2016-09-06 駆虫薬の大環状ラクトンを含むミクロスフェア
US15/735,233 US10603278B2 (en) 2015-09-16 2016-09-06 Microspheres containing anthelmintic macrocyclic lactones
CA2989092A CA2989092C (en) 2015-09-16 2016-09-06 Microspheres containing anthelmintic macrocyclic lactones
PT167702133T PT3349726T (pt) 2015-09-16 2016-09-06 Microsferas que contêm lactonas macrocíclicas antihelmínticas
CY20201101059T CY1123554T1 (el) 2015-09-16 2020-11-10 Μικροσφαιριδια που περιεχουν αντιελμινθικες μακροκυκλικες λακτονες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2015A003652A ITUB20153652A1 (it) 2015-09-16 2015-09-16 Microsfere contenenti lattoni macrociclici antielminitici

Publications (1)

Publication Number Publication Date
ITUB20153652A1 true ITUB20153652A1 (it) 2017-03-16

Family

ID=54884228

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2015A003652A ITUB20153652A1 (it) 2015-09-16 2015-09-16 Microsfere contenenti lattoni macrociclici antielminitici

Country Status (19)

Country Link
US (1) US10603278B2 (it)
EP (1) EP3349726B1 (it)
JP (1) JP6781717B2 (it)
KR (2) KR102752755B1 (it)
AU (1) AU2016321801B2 (it)
CA (1) CA2989092C (it)
CY (1) CY1123554T1 (it)
DK (1) DK3349726T3 (it)
ES (1) ES2848559T3 (it)
HR (1) HRP20201783T1 (it)
HU (1) HUE052553T2 (it)
IT (1) ITUB20153652A1 (it)
LT (1) LT3349726T (it)
PL (1) PL3349726T3 (it)
PT (1) PT3349726T (it)
RS (1) RS61100B1 (it)
SI (1) SI3349726T1 (it)
SM (1) SMT202000625T1 (it)
WO (1) WO2017045966A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
MX2021010043A (es) 2019-02-21 2022-07-19 Chromadex Inc Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
CA3138263A1 (en) * 2019-05-03 2020-11-12 Intervet International B.V. Injectable pharmaceutical compositions and uses thereof
PT4153133T (pt) * 2020-05-20 2024-01-12 Intervet Int Bv Composições farmacêuticas injetáveis e utilizações das mesmas
JP2025521784A (ja) 2022-06-30 2025-07-10 ヴィルバック Pk/pd相互作用に関連する非ヒト哺乳類の化学的去勢におけるデスロレリンの使用
CN115040487B (zh) * 2022-07-04 2023-04-25 湖北工业大学 一种几丁质酶响应性伊维菌素微球及其制备方法和应用
CN116531337A (zh) * 2023-04-20 2023-08-04 中国农业科学院兰州畜牧与兽药研究所 一种莫西菌素缓释微球及其制备方法和应用
WO2025190964A1 (en) 2024-03-12 2025-09-18 Virbac Parenteral modoflaner for the control of ectoparasites

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525307A1 (en) * 1991-07-23 1993-02-03 American Cyanamid Company Stable compositions for parenteral administration and their use
WO1999043304A1 (en) * 1998-02-25 1999-09-02 John Claude Savoir Stable shaped particles of crystalline organic compounds
EP1197207A2 (en) * 2000-10-10 2002-04-17 American Cyanamid Company Stable compositions for parenteral administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054664T3 (es) 1986-03-12 1994-08-16 American Cyanamid Co Compuestos macrolidos.
DE3750355T2 (de) 1986-09-12 1995-04-06 American Cyanamid Co 23-Oxo(keto) und 23-Imino-Derivate von LL-F28249-Verbindungen.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
PL339864A1 (en) 1997-09-30 2001-01-15 Lilly Co Eli Preparation containing 2-methylthiene benzodiazepin
AU781682B2 (en) 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AUPR602501A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
SI1844765T1 (sl) * 2003-06-13 2015-05-29 Skendi Finance, Ltd. Formulacija estradiola in progesterona s počasnim sproščanjem
KR20140136005A (ko) 2012-03-13 2014-11-27 바이엘 뉴질랜드 리미티드 지속성 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525307A1 (en) * 1991-07-23 1993-02-03 American Cyanamid Company Stable compositions for parenteral administration and their use
WO1999043304A1 (en) * 1998-02-25 1999-09-02 John Claude Savoir Stable shaped particles of crystalline organic compounds
EP1197207A2 (en) * 2000-10-10 2002-04-17 American Cyanamid Company Stable compositions for parenteral administration

Also Published As

Publication number Publication date
HUE052553T2 (hu) 2021-05-28
KR20180052559A (ko) 2018-05-18
CY1123554T1 (el) 2022-03-24
CA2989092C (en) 2023-10-03
KR102752755B1 (ko) 2025-01-10
CA2989092A1 (en) 2017-03-23
US20180177730A1 (en) 2018-06-28
DK3349726T3 (da) 2020-11-23
KR20240108529A (ko) 2024-07-09
PL3349726T3 (pl) 2021-04-06
PT3349726T (pt) 2020-11-23
EP3349726B1 (en) 2020-11-04
US10603278B2 (en) 2020-03-31
WO2017045966A1 (en) 2017-03-23
EP3349726A1 (en) 2018-07-25
RS61100B1 (sr) 2020-12-31
SI3349726T1 (sl) 2020-12-31
SMT202000625T1 (it) 2021-01-05
LT3349726T (lt) 2021-02-10
AU2016321801B2 (en) 2021-11-25
JP2018527291A (ja) 2018-09-20
JP6781717B2 (ja) 2020-11-04
AU2016321801A1 (en) 2018-01-04
HRP20201783T1 (hr) 2021-01-22
ES2848559T3 (es) 2021-08-10

Similar Documents

Publication Publication Date Title
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3305788T3 (da) Janus-kinase-hæmmer
DK3129350T3 (da) Makrocyklusser
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3310450T3 (da) Olie-vand-separator
KR20180084915A (ko) 구조체
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
EP3381654A4 (en) Liquid blow molding method
ITUB20153652A1 (it) Microsfere contenenti lattoni macrociclici antielminitici
EP3393959A4 (en) GRAB
EP3343603A4 (en) STRUCTURE
EP3363322A4 (en) Hair extender
EP3308781A4 (en) BLOOD PRESSURE CENTER
EP3390240A4 (en) LOADING STRUCTURE
DE112015006486A5 (de) Inkubationsrinne
EP3390373C0 (en) DOTA SUMMARY
EP3548009A4 (en) POLYMERIC NANOPARTICLES
DK3274482T3 (da) Stenborsknop
EP3377179A4 (en) DEUTERED EPI-743